7-fluoro-6-methoxy-1-tetralone | 125067-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 7-fluoro-6-methoxy-1-tetralone
• 英文别名: 7-fluoro-6-methoxy-3,4-dihydronaphthalen-1(2H)-one；7-fluoro-6-methoxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 125067-57-4
• 化学式: C₁₁H₁₁FO₂
• 分子量: 194.206
• InChiKey: AHRLJDRNPULHKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-fluoro-6-methoxy-1-tetralone 在 氢溴酸 、 溶剂黄146 作用下， 以94%的产率得到7-fluoro-6-hydroxy-3,4-dihydro-2H-naphthalen-1-one
  参考文献：
  名称：

  Novel structural features increase the antioxidant effect of estrogen analogues on low density lipoprotein

  摘要：

  Many known estrogens, both natural and synthetic, may act as antioxidants. We designed and synthesized 22 novel estrogen analogues with different ring junctions or substitutions, such as fluorine. We studied the antioxidant capacity in vitro of 35 synthetic estrogen analogues in aqueous lipoprotein solution by monitoring the formation of conjugated dienes. In addition to a free C-3 hydroxyl group, the two most active antioxidants had either a methyl group at C-4 and a six-carbon D-ring, or a fluorine atom at C-2 and an unsaturated B-ring. Extension of the D-ring increased the antioxidant capacity of 6-oxa estrogens. Compounds with a fluorine atom at C-2 were similar or more potent antioxidants compared with the principal endogenous estrogen, 17 beta-estradiol. In compounds with a substituted C-3 hydroxyl group, the antioxidant capacity could be significantly increased by additional double bonds in the C- or D-rings. In conclusion, we show that the antioxidant capacity of estrogen analogues could be increased by structural changes. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.jsbmb.2015.08.001
• 作为产物：
  描述：

  6-fluoro-7-methoxy-1,2,3,4-tetrahydronaphthalene 在 chromium(VI) oxide 、 硫酸 作用下， 以 水 、 丙酮 为溶剂， 反应 18.5h， 以69.8%的产率得到7-fluoro-6-methoxy-1-tetralone
  参考文献：
  名称：

  2 位氟类固醇雌激素的一些 8α 类似物的合成、结构和生物学特性

  摘要：

  实现了 2 位氟的类固醇雌激素的 8α 类似物的全合成。以17β-乙酰氧基-2-氟-3-甲氧基-8α-estra-1,3,5(10)-triene为例研究了这些化合物的结构特征。结果表明，2-氟取代的类固醇雌激素的 8α 类似物具有低促子宫活性，并保留了骨保护和降低胆固醇的活性。

  DOI：

  10.1134/s1068162007030041

文献信息

• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。
• Transformations of Organic Molecules with F-TEDA-BF4 in Ionic Liquid Media
  作者：Jasminka Pavlinac、Marko Zupan、Stojan Stavber

  DOI：10.3390/molecules14072394

  日期：——

  ([bmim][PF(6)], 3). The range of substrates included alkyl substituted phenols 4a-c, 9, 13, 1,1-diphenylethene (15), alkyl aryl ketones 19-22, aldehydes 23-25 and methoxy-substituted benzene derivatives 26-30. The evaluation of the outcome of reactions performed in IL media in comparison to those of the corresponding reactions in conventional organic solvents revealed that the transformations in IL

  在亲水离子液体 (IL) 1-丁基-3-甲基-咪唑鎓四氟硼酸盐 ([bmim][BF(4)], 2) 中研究了 F-TEDA-BF(4) (1) 对有机分子的转化和疏水性 IL 1-丁基-3-甲基-咪唑鎓六氟磷酸盐 ([bmim][PF(6)], 3)。底物范围包括烷基取代酚 4a-c, 9, 13, 1,1-二苯基乙烯 (15)、烷基芳基酮 19-22、醛 23-25 和甲氧基取代苯衍生物 26-30。与在常规有机溶剂中的相应反应相比，在 IL 介质中进行的反应结果的评估表明，IL 中的转化效率和选择性较低。还研究了存在亲核试剂（MeOH、H(2)O、MeCN）对反应过程的影响。
• Solvent directing immediate fluorination of aromatic ketones using 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)
  作者：Stojan Stavber、Marjan Jereb、Marko Zupan

  DOI：10.1039/b003488f

  日期：——

  Reactions of aryl alkyl ketones with 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (AccufluorTM NFTh) in methanol result in selective and almost quantitative formation of the corresponding α-fluoroketones, while in acetonitrile exclusive fluorofunctionalisation of the activated aromatic ring take place.

  芳基烷基酮与 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (AccufluorTM NFTh) 在甲醇中的反应导致选择性和几乎定量地形成相应的 α-氟酮，而在乙腈中，活化的芳环发生排他性的氟官能化。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2015200709A1

  公开（公告）日：2015-12-30

  The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本公开涉及治疗癌症和肿瘤疾病的组合物和方法。本文提供了替代吡啶衍生物化合物和包含该化合物的制药组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，该化合物和组合物对于治疗癌症，例如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用途。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US20160332970A1

  公开（公告）日：2016-11-17

  The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本公开涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了取代吡啶衍生物化合物和包含该化合物的制药组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用处。此外，该化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用处。